PROGRAM CHAIR
Linda Duska, MD, MPH
Associate Dean for Clinical Research
University of Virginia
School of Medicine Clinical Trials Office
Ivy Translational Research Building
Charlottesville, VA
SPEAKER FACULTY
Shannon N. Westin, MD, MPH, FACOG
Associate Professor
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, TX
PROGRAM OVERVIEW
This enduring activity will cover the treatment and management of patients with advanced and/or recurrent endometrial cancer.
TARGET AUDIENCE
This activity is intended for US-based gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers including endometrial cancer.
LEARNING OBJECTIVES
On completing the program, attendees should be able to:
- Describe the immune system pathology associated with EC and the use of immune checkpoint inhibitors to overcome tumor cell evasion
- Review the MOAs and clinical profiles associated with immune checkpoint inhibitors used alone and in combination with additional targeted agents including TKIs for patients with advanced and/or recurrent EC
- Design individualized therapeutic regimens for patients with advanced and/or recurrent EC that account for important patient-specific characteristics
- Discuss side effects and toxicities associated with immune checkpoint inhibitors used alone and in combination with additional targeted agents including TKIs for patients with advanced and/or recurrent EC and strategies to manage them
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved and/or interested in the therapeutic management of patients with advanced and/or recurrent endometrial cancer.
CNE Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty Member | Disclosure |
| Linda Duska, MD, MPH | Dr. Duska has served on the advisory board for Astra Zeneca, Genentech/Roche, Morphotek, Merck, and Cue Biopharma. She has served as a local PI or co-PI for Genentech/Roche, the GOG 3008 trial, GOG 3005 trial, Tesaro, Pfizer, GSK/Novartis, Morab, Morphotek, Merck, Aduro Biotech Clinical Trials, Syndax, Ludwig, LEAP Therapeutics, Eisai, Lycera, Inovio, Advaxis, and Cerulean. She has received research grants from GSK/Novartis and Merck. She has served on the Data Safety Monitoring Board for Inovio. She has provided oncology expert review for Advance Medical, Parexel, Expert Review, and ClearView Health Care. She serves on the Editorial Board for British Journal of OB/GYN. She has written for UpToDate. She has served as a protocol reviewer for competitive award in the state of California. She has received royalties for book chapters from Elsevier and JB Learning. She serves as the editor-in-chief at ASCO Connection. She serves as the co-chair of The Uterine Task Force for the National Cancer Institute. She provided clinical trial support to Novartis. |
| Shannon N. Westin, MD, MPH, FACOG | Dr. Westin reports that she serves as a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Merck, Pfizer, Circulogene, Zentalis, and Eisai. She has also done contracted research on behalf of her institution for clinical trials: AstraZeneca, Clovis Oncology, GSK/Tesaro, Roche/Genentech, Novartis, Bayer, ArQule, and Cotinga Pharmaceuticals. |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: November 9, 2020
EXPIRATION DATE: November 9, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
